Menu
PA offers fully human antibody development using transgenic mice. Precision Antibody uses its proprietary procedures and platform to rapidly generate specific therapeutic monoclonal antibodies. We are capable to developing a large number of antigen-specific clones producing fully human IgG in about 60 days. Please inquire.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there? ➜
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
Fully human monoclonal antibody development –
Precision Antibody has established an exclusive service arrangement with Trans Chromosomics (TC) to introduce a new service of developing Fully Human Monoclonal Antibody in 60 DAYS.
The drug antibody development is a lengthy process spanning target discovery, target validation, lead generation, preclinical studies to clinical trials. With the use of TC mice, we can significantly shorten the time for lead generation saving up to two years in the drug antibody development process.
To obtain human functional antibodies (neutralizing, internalizing, or agonistic) with desired affinity, the use of humanized mice to develop fully human monoclonal antibodies offers several advantages over the other methods.
TC mice stand out from the other commercialized humanized mice on the market for its significantly high degree of immunocompetence.
We pride ourselves on our customer service!
